A total of 20 serious infections were treated with piperacillin. These infections included bacteremias (5) , pneumonias (5) , urinary tract infections (5) , soft tissue infections (3), septic arthritis (1) , and osteomyelitis (1) . The most common bacterial pathogen was Pseudomonas aeruginosa, accounting for eight infections. The clinical and bacteriological response rates were 75 and 70%, respectively. Four of the five patients who failed to respond to piperacillin therapy were infected with Pseudomonas. In two patients with Pseudomonas infections clinical relapse was accompanied by the development of piperacillin-resistant P. aeruginosa. The findings suggest that the use of piperacillin as a single agent for the treatment of serious gram-negative infections may be ill-advised, especially if P. aeruginosa is the offending pathogen.
Gram-negative bacterial infections are a major source of morbidity and mortality among hospitalized patients (13) . For several decades the mainstay of treatment for these nosocomial infections has been the aminoglycoside antibiotics. Because these drugs have significant nephrotoxicity and ototoxicity, there has been considerable interest in developing less toxic, alternative agents.
Piperacillin is a new semisynthetic aminobenzylpenicillin with a wide spectrum of activity, including Escherichia coli, Klebsiella, Enterobacter, Proteus, Serratia, Providencia, and Pseudomonas (1, 4, 7, 12) . In vitro, piperacillin is 8-to 16-fold more active than ticarcillin or carbenicillin against Pseudomonas and other gram-negative organisms; hence, it was felt that piperacillin alone might be adequate therapy for these infections (1, 7, 12) .
A problem which has arisen in the treatment ofPseudomonas infections with the semisynthetic penicillins carbenicillin and ticarcillin is the development of resistance to these agents by the offending pathogen (2, 3, 5, 6, (8) (9) (10) (11) . The results of our therapeutic trial in 20 infections indicate that resistance to piperacillin can also occur during the course of therapy of Pseudomonas infection. We report two such instances in our series in whom piperacillin-induced resistance was associated with clinical relapse. These included eight infections with Pseudomonas aeruginosa, two with Acinetobacter calcoaceticus subsp. anitratus, and one each with Morganella morganii, Haemophilus influenzae, Salmonella pullorum, Serratia rubidia, Enterobacter cloacae, and Streptococcus pneumoniae. More than one microorganism (range, 2 to 7) were isolated from the infected site in five infections, one of which was cured and four of which were improved. Among the five patients who failed to respond clinically, four were infected with Pseudomonas, one with a resistant E. cloacae, and one with S. rubidia.
MATERIALS AND METHODS
Three of five bacteremic patients improved with piperacillin. Included in this group were an M. morganii urinary tract infection, an infected decubitus ulcer with Bacteroides vulgatus bacteremia and an S. pullorum infection. The last patient relapsed with recurrent S. pullorum bacteremia after 11 days of piperacillin and 2 weeks of oral trimethoprim-sulfamethoxazole therapy. Prolonged intravenous ampicillin and oral amoxicillin therapy was ultimately effective in curing this patient. Both bacteremic patients who failed to respond to piperacillin therapy had P. aeruginosa infections, one from an infected hemodialysis graft and the other from an intraabdominal source.
Three of the five patients with pneumonia were cured, and one patient improved with piperacillin. Their infecting organisms were S. pneumoniae, H. influenzae, P. aeruginosa, and A. calcoaceticus subsp. anitratus. The fifth patient died with a Pseudomonas pneumonia.
All five urinary tract infections clinically improved with piperacillin therapy. P. aeruginosa was the infecting organism in three episodes whereas two pathogens were isolated from each of the other two cases. One patient had P. aeruginosa and Klebsiella pneumoniae; the other had Proteus vulgaris and E. cloacae. In the latter patient the Enterobacter isolate was resistant to piperacillin and persisted in the urine, but the patient improved clinically with elimination of Proteus.
One patient with a polymicrobial soft tissue infection was cured with piperacillin therapy.
Two other patients with soft tissue infections (one of whom was bacteremic) improved with piperacillin, as did one patient with chronic osteomyelitis. Two additional patients had progression of their illness despite piperacillin therapy. One patient with Pseudomonas arthritis of the knee appeared to respond after 6 weeks of piperacillin therapy. Unfortunately, 6 months later he returned with osteomyelitis of the distal femur due to the same organism. The other patient had an S. rubidia cellulitis and soft tissue ulcer on the plantar surface of the foot. Despite 52 days of piperacillin therapy, the ulcer continued to grow S. rubidia, although the surrounding cellulitis had resolved. Six weeks after discharge, x-ray changes of osteomyelitis became evident.
In two patients infected with Pseudomonas, the organism developed resistance to piperacillin during therapy. In one patient who died with pneumonia the original isolate had an MIC of 1 ,ug/ml. A second isolate 10 days later had an MIC of 128 ,ug/ml. The second patient was bacteremic with an infected hemodialysis graft; the initial isolate of Pseudomonas had an MIC of 8 ,tg/ml. This patient defervesced after piperacillin was started, but fever recurred. Repeat blood cultures after 10 days of therapy grew Pseudomonas with an MIC of 256 ,ug/ml. In the latter patient both isolates were identical by pyocin typing.
One patient with an M. morganii urinary tract infection and bacteremia developed an S. aureus pneumonitis after 7 days of piperacillin therapy, necessitating a change in the antibiotic regimen for this superinfection.
The only symptomatic toxicity noted was the development of ecchymoses in one patient. Interestingly, during a previous hospitalization this patient had developed ecchymoses while receiving carbenicilhin. An Eight patients in this series were infected with P. aeruginosa; only four were cured or improved, the other four patients failed to respond to piperacillin. Furthermore, the only deaths in this series occurred in two patients with Pseuwith Pseudomonas infections.
The use of semisynthetic penicillins in the treatment of Pseudomonas infections is accompanied by the development of in vitro resistance and therapeutic failures in a significant number of patients (2, 3, 5, 6, (8) (9) (10) (11) cillin alone in the therapy of serious gram-negative infections, especially when P. aeruginosa is the offending pathogen.
